CapsoVision (CV) vs Outset Medical (OM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CapsoVision (CV) has outperformed Outset Medical (OM) over the past year, gaining 16.8% versus a loss of 34.5%. CapsoVision is the larger company by market cap ($327.6 million vs $53.0 million), about 6.2 times the size. Outset Medical converts more of its revenue into profit, with a net margin of -68.3% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | OM |
|---|---|---|
| Share price | $6.11 | $2.81 |
| Market cap | $327.56M | $53.03M |
| 1-day change | -3.17% | -3.44% |
| YTD return | -42.84% | -24.26% |
| 1-year return | +16.83% | -34.50% |
| 5-year return | — | -99.61% |
| EPS (TTM) | $-0.42 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.55M | $119.48M |
| Revenue growth (YoY) | +15.29% | +5.09% |
| Net income (latest FY) | $-25.32M | $-81.65M |
| Gross margin | 52.92% | 39.13% |
| Operating margin | -188.25% | -55.83% |
| Net margin | -186.77% | -68.34% |
| 52-week high | $15.37 | $6.49 |
| 52-week low | $4.50 | $2.77 |
| Distance from 52-week high | -60.25% | -56.70% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +55.48% | +172.95% |
| Average volume | 173.59K | 140.40K |
| Shares outstanding | 53.61M | 18.87M |
| Employees | 99 | 310 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CapsoVision is about 6.2 times larger than Outset Medical by market value ($327.56M vs $53.03M).
- CV has outperformed OM by 51.3 percentage points over the past year.
- Outset Medical is more profitable, keeping -68.3 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
- CapsoVision grew revenue faster in its latest fiscal year (+15.29% vs +5.09%).
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees
CV vs OM FAQ
Which is bigger, CapsoVision or Outset Medical?
CapsoVision (CV) is larger, with a market capitalization of $327.56M compared with $53.03M for Outset Medical (OM).
Which stock has performed better over the past year, CV or OM?
CV returned +16.83% over the past 12 months, compared with -34.50% for OM (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and Outset Medical in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.